Galectin-9—An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy
International Journal of Molecular Sciences · 19.08.2025 · 26 (16) · 7998
DOI: 10.3390/ijms26167998 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.08.2025. Verfasst von Anastasia Iris Karkempetzaki und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: Galectins, Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 248 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIH/NCI.
Abstract (Originalsprache)
Galectin-9 (Gal-9, LGALS9) is a member of the family of carbohydrate-binding lectins known as galectins. Galectins bind a diverse repertoire of galactose-bearing glycoprotein receptors expressed across multiple cell types. These interactions elicit a broad spectrum of pleiotropic effects important in both normal physiology and disease pathogenesis. Gal-9 contains two separate carbohydrate recognition domains with overlapping yet also divergent binding affinities for distinct glycostructures. This tandem repeat motif enables fine-tuning of its various biological functions. Additional control of Gal-9 activity is provided via multiple gene variants, protein isoforms, tissue distribution, and cell type-associated glycoprotein binding profiles. Within the tumor microenvironment, Gal-9 interacts with immune, non-immune, and cancer cells to influence malignant progression. Its binding of the premier immune checkpoint glycoreceptors, T-cell immunoglobulin and mucin-domain-containing-3 (TIM-3) and programmed cell death protein 1 (PD-1), places Gal-9 apart as a burgeoning target for immunotherapy. In this review, we delve into important aspects of Gal-9 immunobiology in tumorigenesis, including glycobiological and lineage-dependent functions. We further examine Gal-9 as a promising new glyco-immune checkpoint target for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- Program of Glyco-Immunology and Oncology (PGIO), Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- School of Medicine, University of Crete, 71003 Heraklion, Greece.
- Department of Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Förderung
- NCI NIH HHS
- NIH HHS
- NIH/NCI
Zitieren
APA
Karkempetzaki, A. I., Schatton, T., & Barthel, S. R. (2025). Galectin-9—An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy. International Journal of Molecular Sciences, 26(16), 7998. https://doi.org/10.3390/ijms26167998
Vancouver
Karkempetzaki AI, Schatton T, Barthel SR. Galectin-9—An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy. International Journal of Molecular Sciences. 2025;26(16):7998. doi:10.3390/ijms26167998
BibTeX
@article{Karkempetzaki2025,
author = {Karkempetzaki, Anastasia Iris and Schatton, Tobias and Barthel, Steven R},
title = {Galectin-9—An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {16},
pages = {7998},
doi = {10.3390/ijms26167998}
}
EUVIMED